Synthetic Biologics (NYSEAMERICAN:SYN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “

Separately, BidaskClub downgraded Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. Three equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.92.

Synthetic Biologics (NYSEAMERICAN:SYN) traded up $0.00 during trading hours on Thursday, hitting $0.53. The stock had a trading volume of 429,789 shares, compared to its average volume of 882,458. The company has a market cap of $67.43, a P/E ratio of -2.39 and a beta of 1.13. Synthetic Biologics has a 1 year low of $0.41 and a 1 year high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its earnings results on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/synthetic-biologics-syn-lowered-to-sell-at-zacks-investment-research/1806264.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with Analyst Ratings Network's FREE daily email newsletter.